L. Bosquée

发表

Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.

K. Nackaerts, M. Socinski, F. Shepherd, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Serial Measurements of Mesothelioma Serum Biomarkers in Asbestos-Exposed Individuals: A Prospective Longitudinal Cohort Study

S. Vansteelandt, K. Nackaerts, J. V. van Meerbeeck, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage Non–Small-Cell Lung Cancer

G. Scagliotti, E. Felip, J. von Pawel, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Randomized Phase II Pharmacokinetic and Pharmacodynamic Study of Indisulam as Second-Line Therapy in Patients with Advanced Non–Small Cell Lung Cancer

P. Ellis, J. von Pawel, D. Talbot, 2007, Clinical Cancer Research.

Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC).

K. Nackaerts, M. Socinski, F. Shepherd, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cervical lymphadenitis caused by a fastidious mycobacterium closely related to Mycobacterium genavense in an apparently immunocompetent woman: diagnosis by culture-free microbiological methods

B. Hirschel, L. Rigouts, J. Palomino, 1995, Journal of clinical microbiology.

Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non–Small-Cell Lung Cancer

G. Fasola, D. Atanackovic, J. Vansteenkiste, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma ( EORTC trial 08956 ) 1

G. Giaccone, G. Scagliotti, E. Smit, 2009 .

Soluble Mesothelin, Megakaryocyte Potentiating Factor, and Osteopontin as Markers of Patient Response and Outcome in Mesothelioma

K. Nackaerts, E. Kellen, J. V. van Meerbeeck, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A multicenter, randomized phase III study of docetaxel + cisplatin (DC) vs docetaxel + carboplatin (DCb) vs vinorelbine + cisplatin (VC) in chemotherapy-naive patients (Pts) with advanced and metastatic non-small cell lung cancer (NSCLC)

F. Fossella, M. Millward, J. Bérille, 2000 .

Gefitinib monotherapy in advanced non-small cell lung cancer (NSCLC): Experience from a large, Western community implementation study

K. Nackaerts, J. Canon, J. Vansteenkiste, 2006 .

ARandomized Phase II Pharmacokinetic and Pharmacodynamic Study of Indisulam as Second-Line Therapy in Patients with Advanced Non ^ Small Cell Lung Cancer

P. Ellis, D. Talbot, C. Norbury, 2007 .

MAGE-A3 cancer immunotherapeutic in resected stage IB-III NSCLC patients with or without sequential or concurrent chemotherapy.

G. Fasola, D. Atanackovic, J. Vansteenkiste, 2012 .

Tecemotide ( L-BLP 25 ) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer ( START ) : a randomised , double-blind , phase 3 trial

M. Socinski, F. Shepherd, R. Ramlau, 2013 .

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.

M. Socinski, F. Shepherd, R. Ramlau, 2014, The Lancet. Oncology.

Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study

A. Navarro, R. Huber, M. Thomas, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Moderate dose-escalation of combination chemotherapy with concomitant thoracic radiotherapy in limited-disease small-cell lung cancer: prolonged intrathoracic tumor control and high central nervous system relapse rate. Groupe d'Oncologie-Pneumologie Clinique de l'Université Catholique de Louvain, Br

J. Canon, H. van de Velde, Y. Humblet, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

High-dose chemo-radiotherapy cycles for LD small cell lung cancer patients using G-CSF and blood stem cells.

Y. Humblet, M. Symann, P. Weynants, 1996, Bone marrow transplantation.

Sequential high-dose ICE chemotherapy with circulating progenitor cells (CPC) in small cell lung cancer: an EBMT study.

M. Marangolo, L. Perey, Y. Humblet, 1996, Bone marrow transplantation.

Frontline gemcitabine and cisplatin based chemotherapy in patients with NSCLC inoperable brain metastases.

L. Bosquée, N. Barthélémy, V. Quadvlieg, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Original article Gemcitabine plus etoposide in chemonaive extensive disease small-cell lung cancer: A multi-centre phase II study

J. Vansteenkiste, C. Manegold, A. Hanauske, 2004 .

Brief Report: An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer

Tuan S. Nguyen, G. Scagliotti, S. Novello, 2016 .

Peripheral blood progenitor cell collections in cancer patients: analysis of factors affecting the yields.

V. Bours, G. Jerusalem, B. Sautois, 1999, Haematologica.

Increased TGFβ1 plasma level in patients with lung cancer: potential mechanisms

A. Albert, J. David, T. Bury, 2002, European journal of clinical investigation.

Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.

K. Nackaerts, E. Kellen, J. V. van Meerbeeck, 2010, American journal of respiratory and critical care medicine.

Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT)

J. V. van Meerbeeck, J. Canon, Y. Humblet, 2016, PloS one.

START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer.

M. Socinski, F. Shepherd, R. Ramlau, 2013 .

Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: A feasibility study by the European Group for Blood and Marrow Transplantation.

M. Marangolo, L. Perey, Y. Humblet, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gemcitabine plus etoposide in chemonaive extensive disease small-cell lung cancer: a multi-centre phase II study.

J. von Pawel, U. Gatzemeier, J. Vansteenkiste, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer.

G. Giaccone, E. Smit, C. Legrand, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062.

C. Fink, A. Dingemans, J. V. van Meerbeeck, 2011, European journal of cancer.

A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer.

G. Scagliotti, Keunchil Park, F. de Marinis, 2010, Lung cancer.

Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine.

C. Dooms, K. Nackaerts, J. Vansteenkiste, 2003, Lung cancer.

Increased IL-6 and TGF-beta1 concentrations in bronchoalveolar lavage fluid associated with thoracic radiotherapy.

D. Cataldo, A. Albert, N. Barthelemy-Brichant, 2004, International journal of radiation oncology, biology, physics.

The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor.

K. Nackaerts, E. Kellen, J. V. van Meerbeeck, 2012, Chest.

Is an evidence-based approach realistic in non-small cell lung cancer (NSCLC)?

P. Coucke, L. Bosquée, N. Barthélémy, 2008 .

The Importance of Accurate Lymph Node Staging in Early and Locally Advanced Non-small Cell Lung Cancer: An Update on Available Techniques

Edward S. Kim, L. Bosquée, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

An Open‐Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC‐A12) as a First‐Line Therapy in Patients With Advanced Nonsquamous Non–Small Cell Lung Cancer

Tuan S. Nguyen, G. Scagliotti, S. Novello, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II study of docetaxel in the treatment of patients with advanced non-small cell lung cancer in routine daily practice.

R. Stupp, J. Pujol, J. Douillard, 2000, Lung cancer.

[Lung cancer. Epidemiology and etiologic factors].

R. Louis, L. Bosquée, N. Frusch, 2007, Revue medicale de Liege.

Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study

K. Nackaerts, J. Canon, J. Vansteenkiste, 2006, European Respiratory Journal.

A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956).

G. Giaccone, G. Scagliotti, E. Smit, 2005, Lung cancer.

Thrombo-Embolic Events in Cancer Patients with Impaired Renal Function

J. Canon, A. Awada, J. Baurain, 2014 .

Randomized phase 3 trial of amrubicin versus topotecan as second-line treatment for small cell lung cancer (SCLC)

K. Nackaerts, M. Socinski, F. Shepherd, 2012 .

Efficacy of Erlotinib in patients (PTS) with advanced non-small-cell lung cancer (NSCLC) relative to clinical charesteristics : subset analyses from the trust study

G. Scagliotti, R. Pirker, L. Bosquée, 2008 .

Abrupt Severe Chest Pain and Vomiting: Remember to Think of a Ruptured Oesophagus (Boerhaave Syndrome)

L. Bosquée, N. Villalba, D. Ali, 2019, European journal of case reports in internal medicine.

Randomized Multicenter Phase II Study of Larotaxel (XRP9881) in Combination with Cisplatin or Gemcitabine as First-Line Chemotherapy in Nonirradiable Stage IIIB or Stage IV Non-small Cell Lung Cancer

J. Vansteenkiste, P. Zatloukal, N. Dohollou, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[Paraneoplastic endocrine syndromes: diagnosis and management].

A. Beckers, S. Vandeva, H. Valdés-Socin, 2009, Revue medicale suisse.

An unusual cause of portal hypertension in a cirrhotic patient

L. Bosquée, D. Ali, Y. Gorur, 2019, International Journal of Medical Reviews and Case Reports.

Measles-induced Acute Disseminated Encephalomyelitis in a Non-vaccinated Patient

L. Bosquée, N. Villalba, D. Ali, 2020, European Journal of Case Reports in Internal Medicine.

[Diabetes insipidus in a patient with small-cell lung cancer: a paradox?].

J. Legros, F. Bustin, F. Schleich, 2005, Annales d'endocrinologie.

Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.

K. Nackaerts, E. Kellen, J. V. van Meerbeeck, 2010, American journal of respiratory and critical care medicine.

Randomized phase II study (EORTC 08062) of amrubicin as single agent or in combination with cisplatin versus etoposide-cisplatin as first-line treatment in patients (pts) with extensive disease small cell lung cancer (ED SCLC).

A. Dingemans, J. Jassem, P. Lorigan, 2010 .